EP4469047A4 - Wässrige cevimelinzusammensetzungen und verfahren zur verwendung - Google Patents

Wässrige cevimelinzusammensetzungen und verfahren zur verwendung

Info

Publication number
EP4469047A4
EP4469047A4 EP23747794.8A EP23747794A EP4469047A4 EP 4469047 A4 EP4469047 A4 EP 4469047A4 EP 23747794 A EP23747794 A EP 23747794A EP 4469047 A4 EP4469047 A4 EP 4469047A4
Authority
EP
European Patent Office
Prior art keywords
cevimelin
compositions
aqueous
methods
cevimelin compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23747794.8A
Other languages
English (en)
French (fr)
Other versions
EP4469047A2 (de
Inventor
Roland Bodmeier
Chin-Ming Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotheravision Inc
Original Assignee
Biotheravision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheravision Inc filed Critical Biotheravision Inc
Publication of EP4469047A2 publication Critical patent/EP4469047A2/de
Publication of EP4469047A4 publication Critical patent/EP4469047A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP23747794.8A 2022-01-25 2023-01-25 Wässrige cevimelinzusammensetzungen und verfahren zur verwendung Pending EP4469047A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2022013586 2022-01-25
PCT/US2023/061202 WO2023147318A2 (en) 2022-01-25 2023-01-25 Aqueous cevimeline compositions and methods of use

Publications (2)

Publication Number Publication Date
EP4469047A2 EP4469047A2 (de) 2024-12-04
EP4469047A4 true EP4469047A4 (de) 2026-03-04

Family

ID=87472506

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23747794.8A Pending EP4469047A4 (de) 2022-01-25 2023-01-25 Wässrige cevimelinzusammensetzungen und verfahren zur verwendung

Country Status (3)

Country Link
EP (1) EP4469047A4 (de)
JP (1) JP2025502242A (de)
WO (1) WO2023147318A2 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200115377A1 (en) * 2018-10-10 2020-04-16 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US20210369686A1 (en) * 2018-10-06 2021-12-02 Biotheravision Llc Ophthalmic preparations of muscarinic agonist and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2493474B1 (de) * 2009-10-30 2019-09-04 Intratus, Inc. Verfahren und zusammensetzungen für verzögerte wirkstofffreisetzung
AU2019214557A1 (en) * 2018-02-05 2020-08-20 Cellixbio Private Limited Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210369686A1 (en) * 2018-10-06 2021-12-02 Biotheravision Llc Ophthalmic preparations of muscarinic agonist and methods of use
US20200115377A1 (en) * 2018-10-10 2020-04-16 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia

Also Published As

Publication number Publication date
WO2023147318A3 (en) 2023-09-21
WO2023147318A2 (en) 2023-08-03
TW202329958A (zh) 2023-08-01
JP2025502242A (ja) 2025-01-24
EP4469047A2 (de) 2024-12-04

Similar Documents

Publication Publication Date Title
EP4189088A4 (de) Adar-abhängige editierzusammensetzungen und verfahren zur verwendung davon
EP4244358A4 (de) Rna-editierungszusammensetzungen und verfahren zur verwendung
EP4022059A4 (de) Oligonukleotidzusammensetzungen und verfahren zur verwendung davon
EP4412606A4 (de) Pi3k-alpha-inhibitoren und verfahren zur verwendung davon
EP4566674B1 (de) Antikörperzusammensetzungen und verfahren zur verwendung davon
EP4061940A4 (de) Rekombinasezusammensetzungen und verfahren zur verwendung
EP4422645A4 (de) Oligonukleotidzusammensetzungen und verfahren zur verwendung davon
EP3761972A4 (de) Bioreaktive zusammensetzungen und verfahren zur verwendung davon
EP3983386A4 (de) Acss2-hemmer und verfahren zur verwendung
EP4138854A4 (de) Verkappungsverbindungen, zusammensetzungen und verfahren zur verwendung davon
EP4072436A4 (de) Heftgerät und verfahren zur verwendung
EP4486901A4 (de) Zusammensetzungen und verfahren zur genomeditierung
EP4216727A4 (de) Oligosaccharidzusammensetzungen und verfahren zur verwendung
EP4522583A4 (de) Pi3k-alpha-hemmer und verfahren zur verwendung davon
EP3934426A4 (de) Konservierungszusammensetzungen und verfahren zur verwendung davon
EP4192958A4 (de) Zusammensetzungen und verfahren zur erhöhung der proteinexpression
EP3941909A4 (de) Pi4-kinase-inhibitoren und verfahren zur verwendung davon
EP4426314A4 (de) Pi3k-alpha-inhibitoren und verfahren zur herstellung und verwendung davon
EP4437104A4 (de) Komplementfaktor-b-modulierende zusammensetzungen und verfahren zur verwendung davon
EP4142740A4 (de) Zusammensetzungen und verfahren zur verwendung davon
EP4412617A4 (de) Neuartige pikfyve-hemmer und verfahren zur verwendung davon
EP3983400C0 (de) Chinazolinylinverbindungen und verfahren zur verwendung
EP4255503A4 (de) Zusammensetzungen und verfahren zur verwendung davon
EP4199751A4 (de) Zusammensetzungen und verfahren zur stimmungsverbesserung
EP3735246A4 (de) Mito-lanidamin, zusammensetzungen und verfahren zur verwendung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240826

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40119902

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20260130

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/438 20060101AFI20260126BHEP

Ipc: A61K 31/33 20060101ALI20260126BHEP

Ipc: A61K 31/341 20060101ALI20260126BHEP

Ipc: A61K 31/4747 20060101ALI20260126BHEP